Merger with Aravive Biologics, Inc. (Tables)

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Schedule of Estimate Purchase Price Fair Value Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed

The estimate of the purchase price for the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed, were as follows.

	Amount
	(in thousands)
Consideration
Common stock issued - 5,141,915 shares issued at $7.26 per share	$	37,331
Transaction costs		2,076
Total consideration	$	39,407
Assets acquired and liabilities assumed
Cash	$	5,277
In-process research and development		38,313
Assembled workforce		366
Deferred revenue		(1,517	)
Contingent payable		(264	)
Other assets and liabilities		(2,768	)
Total net assets acquired	$	39,407